The Lancet HIV· Kim Steegen, Jeremy Nel, Erin H Smeijsters, Chijioke N Umunnakwe, Karabo Mophiring, Sean Currin, Wouter M Tiel Groenestege, Matthijs van Luin, Lucas E Hermans, Hugo A Tempelman, Lucia Hans, Lise Jamieson, Siphamandla Gumede, Athini Nyatela, Willem D F Venter, Monique Nijhuis, Annemarie M J Wensing·· 2026-09-03AI 评分53
ITREMA-2 两中心前瞻性实施研究:血浆多替拉韦暴露检测识别 HIV 耐药高风险人群
[Articles] Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa
AI 导读
南非两中心开展的前瞻性实施研究 ITREMA-2 显示,实验室发起的反射性血浆多替拉韦暴露检测可作为客观、成本效益较高的策略,用于预测不存在多替拉韦耐药并支持依从性管理,从而帮助做出及时、个体化的治疗决策。研究作者认为,反射性多替拉韦暴露检测有望改善临床决策和治疗结局,并强化项目化场景下的 HIV 治疗与耐药监测流程。
来源:The Lancet HIV · thelancet.com